U.S. markets closed

Minerva Neurosciences, Inc. (NERV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.8600+0.0300 (+1.06%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.8300
Open2.8900
Bid2.9900 x 1300
Ask3.0000 x 1100
Day's Range2.6600 - 2.9200
52 Week Range1.8100 - 15.2150
Volume409,045
Avg. Volume782,483
Market Cap122.049M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.5200
Earnings DateMar 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.90
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings
    Benzinga

    The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings

    Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA rulings and clinical readouts. Morphic Holding Inc (NASDAQ: MORF) was among the biggest gainers of the week after the company reported a positive early-stage readout in inflammatory bowel disease patients. M&A momentum continued, as Amgen Inc. (AMGN) announced a deal to buy Five Prime Therapeutics, Inc. (NASDAQ: FPRX) in an $1.9-billion all-cash deal. Here are the key catalysts for the unfolding week: Conferences Chardan's 3rd Annual Microbiome Medicines Summit: March 8 H.C. Wainwright Global Life Sciences Conference: March 9-11 Barclays Global Healthcare Conference: March 9-11 15th International Conference on Alzheimer's and Parkinson's disease: March 9-14 Clinical Readouts Prothena Corporation plc (NASDAQ: PRTA) will present at the Alzheimer's and Parkinson's disease conference new preclinical data on a treatment for Alzheimer's disease. The treatment targets an anti-tau antibody, which is thought to play a role in the disease. The company says targeting a certain antibody called a novel epitope with PRX005 has shown superior results. The presentation is scheduled for Thursday, March 11, between 7:30 a.m. and 7:45 a.m. Earnings Monday Minerva Neurosciences, Inc. (NASDAQ: NERV) (before the market open) Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) (after the close) Castle Biosciences, Inc. (NASDAQ: CSTL) (after the close) SI-BONE, Inc. (NASDAQ: SIBN) (after the close) Avadel Pharmaceuticals plc (NASDAQ: AVDL) (after the close) View more earnings on IBB Related Link: Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates Tuesday Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (before the market open) Trevena, Inc. (NASDAQ: TRVN) (before the market open) InspireMD, Inc. (NYSE: NSPR) (before the market open) Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) (before the market open) DarioHealth Corp. (NASDAQ: DRIO) (before the market open) Gamida Cell Ltd. (NASDAQ: GMDA) (before the market open) Evelo Biosciences, Inc. (NASDAQ: EVLO) (before the market open) ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (before the market open) Aquestive Therapeutics, Inc. (NASDAQ: AQST) (after the close) Brickell Biotech, Inc. (NASDAQ: BBI) (after the close) Cytosorbents Corporation (NASDAQ: CTSO) (after the close) Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) (after the close) MiMedx Group, Inc. (NASDAQ: MDXG) (after the close) Inari Medical, Inc. (NASDAQ: NARI) (after the close) Lyra Therapeutics, Inc. (NASDAQ: LYRA) (after the close) Wednesday Bio-Path Holdings, Inc. (NASDAQ: BPTH) (before the market open) Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open) BioDelivery Sciences International, Inc. (NASDAQ: BDSI) (before the market open) Clearside Biomedical, Inc. (NASDAQ: CLSD) (after the close) DiaMedica Therapeutics Inc. (NASDAQ: DMAC) (after the close) Five Prime Therapeutics (NASDAQ: FPRX) (after the close) Flexion Therapeutics, Inc. (NASDAQ: FLXN) (after the close) Harpoon Therapeutics, Inc. (NASDAQ: HARP) (after the close) Lantern Pharma Inc. (NASDAQ: LTRN) (after the close) TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (after the close) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) (after the close) Protagonist Therapeutics, Inc. (NASDAQ: PTGX) (after the close) OrthoPediatrics Corp. (NASDAQ: KIDS) (after the close) Thursday Burning Rock Biotech Limited (NASDAQ: BNR) (before the market open) BioXcel Therapeutics, Inc. (NASDAQ: BTAI) (before the market open) Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (before the market open) Achieve Life Sciences, Inc. (NASDAQ: ACHV) (after the close) Capricor Therapeutics, Inc. (NASDAQ: CAPR) (after the close) Lineage Cell Therapeutics, Inc. (NYSE: LCTX) (after the close) Geron Corporation (NASDAQ: GERN) (after the close) Chembio Diagnostics, Inc. (NASDAQ: CEMI) (after the close) Ocular Therapeutix, Inc. (NASDAQ: OCUL) (after the close) Nabriva Therapeutics plc (NASDAQ: NBRV) (after the close) Related Link: Johnson & Johnson Secures Emergency Authorization For Its Single-Shot COVID-19 Vaccine See more from BenzingaClick here for options trades from BenzingaThe Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 StudyThe Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021
    GlobeNewswire

    Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021

    Management to host conference callWALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the fourth quarter and fiscal year ended December 31, 2020 on Monday, March 8, 2021. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 (domestic) or (765) 507-2618 (international) and referring to conference ID number 5663077. A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days. The live webcast can be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at ir.minervaneurosciences.com. The archived webcast will be available on the website beginning approximately two hours after the event for 90 days. About Minerva Neurosciences Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com. Contact: William B. BoniVP, Investor Relations/Corp. CommunicationsMinerva Neurosciences, Inc.(617) 600-7376

  • CLASS ACTION UPDATE for NERV, OTGLY and QS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
    ACCESSWIRE

    CLASS ACTION UPDATE for NERV, OTGLY and QS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / February 8, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.